Bitmine Immersion Technologies ( BMNR ) said on Monday its combined crypto, cash, and “moonshots” holdings total about $10.3 billion. The company reported holdings of 4.53 million ETH, valued at about $1,965 per token, and 195 bitcoin as of March 8, 2026, with its ETH position representing roughly 3.76% of the total supply. It also held $1.2 billion in cash and “moonshot” investments, including a ...
Bitmine Immersion Technologies ( BMNR ) said on Monday its combined crypto, cash, and “moonshots” holdings total about $10.3 billion. The company reported holdings of 4.53 million ETH, valued at about $1,965 per token, and 195 bitcoin as of March 8, 2026, with its ETH position representing roughly 3.76% of the total supply. It also held $1.2 billion in cash and “moonshot” investments, including a $200 million stake in Beast Industries and $14 million in Eightco Holdings. The company said its annualized staking revenue is about $174 million, with roughly 3 million ETH—around 67% of its 4.5 million ETH holdings—currently staked. Its staking operations generated a 7-day annualized yield of 2.91% versus the CESR rate of 2.84%, as it advances the Made in America Validator Network (MAVAN). With its current holdings, it ranks as the largest Ethereum treasury globally and the second-largest corporate crypto treasury overall, behind Strategy, which holds 720,737 bitcoin valued at about $48 billion. More on Bitmine Immersion Technologies Bitmine Vs. Sharplink: One Is A Dilution Trap, The Other Is The Better Ethereum Proxy BitMine Immersion: Tom Lee Calls An Ether Bottom, But I'm Not Convinced Bitmine Immersion: Ethereum's Biggest Public Whale CleanSpark continues to see highest short interest among crypto firms with over $2B market cap BMNR’s Tom Lee predicts March rebound for Crypto, software and MAG‑7 stocks
Oracle Corporation ORCL is set to report third-quarter fiscal 2026 results on March 10, 2026, covering the period from December 2025 through February 2026. Non-GAAP earnings per share are expected to grow 12-14% and be between $1.64 and $1.68 in cc. Non-GAAP earnings per share are expected to grow 16-18% and be between $1.70 and $1.74 in dollar terms. The consensus mark for earnings is pegged at $...
Oracle Corporation ORCL is set to report third-quarter fiscal 2026 results on March 10, 2026, covering the period from December 2025 through February 2026. Non-GAAP earnings per share are expected to grow 12-14% and be between $1.64 and $1.68 in cc. Non-GAAP earnings per share are expected to grow 16-18% and be between $1.70 and $1.74 in dollar terms. The consensus mark for earnings is pegged at $1.70 per share, unchanged over the past 30 days. The figure indicates 15.65% growth from the year-ago period. A series of AI-driven announcements and infrastructure milestones that unfolded during the quarter were among the key factors expected to shape whether Oracle could meet or exceed those targets. Oracle Corporation Price and EPS Surprise Oracle Corporation price-eps-surprise | Oracle Corporation Quote OCI Capacity and RPO Momentum The foundation for potential third-quarter upside was established during fiscal second quarter, when Oracle’s Remaining Performance Obligations surged 438% year over year to $523 billion, driven by new commitments from Meta, NVIDIA and others. Management guided for total cloud revenue growth of 40% to 44% in dollar terms for the fiscal third quarter, noting that near-term capacity availability would enable faster backlog conversion. The Zacks Consensus Estimate for Cloud revenues is pegged at $8.84 billion. Oracle Cloud Infrastructure’s GPU-related revenues grew 177% in the fiscal second quarter, and continued data center deployments were expected to sustain that trajectory through the fiscal third quarter as newly added capacity came online. AI Announcements During Q3 Fiscal 2026 Several notable AI developments took place between December 2025 and February 2026. In December 2025, Oracle and the U.S. Department of Energy announced a collaboration to advance AI and advanced computing initiatives, including the Genesis Mission, signaling Oracle Cloud Infrastructure’s expanding role in government and scientific workloads. That same month, Orac...
Oracle Corporation ORCL is set to report third-quarter fiscal 2026 results on March 10, 2026, covering the period from December 2025 through February 2026. Non-GAAP earnings per share are expected to grow 12-14% and be between $1.64 and $1.68 in cc. Non-GAAP earnings per share are expected to grow 16-18% and be between $1.70 and $1.74 in dollar terms. The consensus mark for earnings is pegged at $...
Oracle Corporation ORCL is set to report third-quarter fiscal 2026 results on March 10, 2026, covering the period from December 2025 through February 2026. Non-GAAP earnings per share are expected to grow 12-14% and be between $1.64 and $1.68 in cc. Non-GAAP earnings per share are expected to grow 16-18% and be between $1.70 and $1.74 in dollar terms. The consensus mark for earnings is pegged at $1.70 per share, unchanged over the past 30 days. The figure indicates 15.65% growth from the year-ago period. A series of AI-driven announcements and infrastructure milestones that unfolded during the quarter were among the key factors expected to shape whether Oracle could meet or exceed those targets. Oracle Corporation Price and EPS Surprise Oracle Corporation Price and EPS Surprise Oracle Corporation price-eps-surprise | Oracle Corporation Quote OCI Capacity and RPO Momentum The foundation for potential third-quarter upside was established during fiscal second quarter, when Oracle’s Remaining Performance Obligations surged 438% year over year to $523 billion, driven by new commitments from Meta, NVIDIA and others. Management guided for total cloud revenue growth of 40% to 44% in dollar terms for the fiscal third quarter, noting that near-term capacity availability would enable faster backlog conversion. The Zacks Consensus Estimate for Cloud revenues is pegged at $8.84 billion. Oracle Cloud Infrastructure’s GPU-related revenues grew 177% in the fiscal second quarter, and continued data center deployments were expected to sustain that trajectory through the fiscal third quarter as newly added capacity came online. AI Announcements During Q3 Fiscal 2026 Several notable AI developments took place between December 2025 and February 2026. In December 2025, Oracle and the U.S. Department of Energy announced a collaboration to advance AI and advanced computing initiatives, including the Genesis Mission, signaling Oracle Cloud Infrastructure’s expanding role in government and s...
Alisson has not travelled to Istanbul for Liverpool’s Champions League last-16 first leg against Galatasaray after sustaining a problem in training. The goalkeeper is understood to have felt minor discomfort after Monday’s session and a decision was taken not to risk taking him to Turkey. Alisson has missed nine matches this season through injury. Giorgi Mamardashvili is poised to make his first a...
Alisson has not travelled to Istanbul for Liverpool’s Champions League last-16 first leg against Galatasaray after sustaining a problem in training. The goalkeeper is understood to have felt minor discomfort after Monday’s session and a decision was taken not to risk taking him to Turkey. Alisson has missed nine matches this season through injury. Giorgi Mamardashvili is poised to make his first appearance since the FA Cup win over Barnsley two months ago, one of 10 starts since arriving in the summer. Mamardashvili has featured in four of the eight Champions League matches, one of which was as a substitute for the injured Alisson in the 1-0 defeat at Galatasaray in September. The Georgia international has kept two clean sheets in his 10 starts, in back-to-back appearances against Real Madrid and Aston Villa in November when Alisson was sidelined with a hamstring problem. Federico Chiesa did not train, after being an unused substitute in Friday’s FA Cup win at Wolves. The midfielder Alexis Mac Allister was forced off with a knee problem in that match but was able to train before flying out with the squad.
In early trading on Monday, shares of Strategy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.4%. Year to date, Strategy has lost about 9.2% of its value. And the worst performing Nasdaq 100 component thus far on the day is Marvell Technology, trading down 5.3%. Marvell Technology is lower by about 0.2% looking at the year to date performance. Two oth...
In early trading on Monday, shares of Strategy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.4%. Year to date, Strategy has lost about 9.2% of its value. And the worst performing Nasdaq 100 component thus far on the day is Marvell Technology, trading down 5.3%. Marvell Technology is lower by about 0.2% looking at the year to date performance. Two other components making moves today are Old Dominion Freight Line, trading down 4.5%, and Applovin, trading up 1.8% on the day. VIDEO: Nasdaq 100 Movers: MRVL, MSTR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - GE HealthCare (GEHC) on Monday said its next-generation diagnostic viewer, View, part of the Genesis Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration. The company said View is a cloud-native, zero-footprint diagnostic imaging viewer designed to streamline radiology workflows and provide radiologists with secure access to diagnostic images fr...
(RTTNews) - GE HealthCare (GEHC) on Monday said its next-generation diagnostic viewer, View, part of the Genesis Radiology Workspace, has received 510(k) clearance from the U.S. Food and Drug Administration. The company said View is a cloud-native, zero-footprint diagnostic imaging viewer designed to streamline radiology workflows and provide radiologists with secure access to diagnostic images from virtually anywhere. Studies cited by the company show radiologists can spend up to 44% of their time on non-interpretive tasks, such as navigating complex software interfaces or waiting for images to load, which can affect productivity and turnaround times. GE HealthCare said the new viewer aims to reduce these inefficiencies by providing a unified workspace that enables faster collaboration and more efficient image review across care teams. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Nvidia fell as soaring energy prices continued to wreak havoc in the stock market Monday and the U.S.-Iran war continued into its second week. Is Nvidia stock a buy or sell now? The Financial Times reported the artificial intelligence chip company is allocating the manufacturing capacity reserved for the H200 chip at Taiwan Semiconductor to Vera Rubin, its next-generation chip.
Nvidia fell as soaring energy prices continued to wreak havoc in the stock market Monday and the U.S.-Iran war continued into its second week. Is Nvidia stock a buy or sell now? The Financial Times reported the artificial intelligence chip company is allocating the manufacturing capacity reserved for the H200 chip at Taiwan Semiconductor to Vera Rubin, its next-generation chip.
Pervis Estupiñán called it “the most important goal of my career”. He does, admittedly, only have 12 to choose from, but to score the winner in a Milan derby is something few players ever experience. It could only feel better for having done it towards the end of a difficult first season in Italian football. The Ecuadorian was billed as a replacement for Theo Hernández when he joined Milan from Br...
Pervis Estupiñán called it “the most important goal of my career”. He does, admittedly, only have 12 to choose from, but to score the winner in a Milan derby is something few players ever experience. It could only feel better for having done it towards the end of a difficult first season in Italian football. The Ecuadorian was billed as a replacement for Theo Hernández when he joined Milan from Brighton last summer, lumbered with unreasonable comparison from the start. Hernández, at his best, was one of the most effective attacking full-backs on the planet. Estupiñán, at 28, is yet to put himself in that conversation, but the hope was that he could offer some of the same directness and ability to get up and down the left flank. After a mixed start, Estupiñán sustained an ankle injury in October. Davide Bartesaghi replaced him in the side. Born in Lombardy to a Milan-supporting father, and developed in the club’s academy, the 20-year-old had a compelling narrative and performances to match. Estupiñán’s opportunities were fewer on his return, and he has not always grasped them as he might like. A series of clumsy touches during a 1-1 draw against relegation battlers Fiorentina in January were held up by critics as evidence of inadequacy. “If this is Estupiñán,” ran one headline from La Gazzetta dello Sport, “then Milan have a problem.” It did not look that way on Sunday as he ran through on goal, controlling Youssouf Fofana’s through-ball with his first touch before crushing a left-footed shot into the near top corner. The culmination of a wonderfully-constructed team move that began – as they so often do – from the feet of Luka Modric. He had dropped all the way back to sit as Milan’s deepest man, effectively in the centre of defence. After feinting left to buy a moment from the Inter press, Modric sent the ball to Fikayo Tomori by the right touchline, who released it immediately to Fofana. The Frenchman, angling across the pitch, exchanged a one-two with Rafael Leão...
Yet, analysts do not think inflation will return to the peak of 11.1% seen in the UK in October 2022. That is because the war in Ukraine also caused spikes in the prices of basic foodstuffs, such as wheat and edible oil, owing to the role of Ukraine in producing those items. That is not the case now.
Yet, analysts do not think inflation will return to the peak of 11.1% seen in the UK in October 2022. That is because the war in Ukraine also caused spikes in the prices of basic foodstuffs, such as wheat and edible oil, owing to the role of Ukraine in producing those items. That is not the case now.
Bet_Noire/iStock via Getty Images TransMedics ( TMDX ) investors are in unfamiliar territory, with the stock effectively treading water since October. The organ transplant leader, which traditionally experiences sharp swings after earnings, gained over 10% after the Q4 report, but gave it back, and more, with the market taking a risk-off approach in recent weeks. I argue that TransMedics has quiet...
Bet_Noire/iStock via Getty Images TransMedics ( TMDX ) investors are in unfamiliar territory, with the stock effectively treading water since October. The organ transplant leader, which traditionally experiences sharp swings after earnings, gained over 10% after the Q4 report, but gave it back, and more, with the market taking a risk-off approach in recent weeks. I argue that TransMedics has quietly become a solid, attractive fundamental story, which no longer requires optimistic imagination. This should result in lower volatility and strong shareholder returns going forward. The recent selloff, after a very strong quarter, provides a buying opportunity. Strong Fourth-Quarter Results From TransMedics With Beats All Around Coming into the fourth-quarter, expectations were relatively high. That is, as investors learned that Q3 is seasonally a lower quarter , while Q4 is typically strong. And, against those elevated expectations, TransMedics delivered , exceeding revenue and earnings estimates. TransMedics Q4'25 Presentation Revenue was up nearly 12% Q/Q, and 32% Y/Y, marking a sequential acceleration , led by US product revenue. Service revenue and Non-US revenues, two lines that are still in the very early innings, continue to grow strongly as well. TransMedics Q4'25 Presentation Liver transplants are still the dominant segment, growing 43% Y/Y and representing over 80% of sales. This is critical to grasp, as management is confident in its ability to make Lung and Heart much larger businesses in the future. This goes to show that TMDX still has another level to go to, in terms of growth, once the rest of the organs reach the commercialization stage. TransMedics Q4'25 Presentation Even though TransMedics still has several programs that are barely contributing to revenue, and it's still building its lower-margin services arm, the operational leverage trajectory here is exceptional. In Q4, operating margins expanded by over 610 bps, despite a 110 bps decline in gross ma...
In early trading on Monday, shares of Live Nation Entertainment topped the list of the day's best performing components of the S&P 500 index, trading up 6.5%. Year to date, Live Nation Entertainment registers a 16.7% gain. And the worst performing S&P 500 component thus far on the day is United Airlines Holdings, trading down 6.3%. United Airlines Holdings is lower by about 22.8% looking at the ye...
In early trading on Monday, shares of Live Nation Entertainment topped the list of the day's best performing components of the S&P 500 index, trading up 6.5%. Year to date, Live Nation Entertainment registers a 16.7% gain. And the worst performing S&P 500 component thus far on the day is United Airlines Holdings, trading down 6.3%. United Airlines Holdings is lower by about 22.8% looking at the year to date performance. Two other components making moves today are Carnival, trading down 6.1%, and Dow, trading up 5.3% on the day. VIDEO: S&P 500 Movers: UAL, LYV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (VKTX 1.00%), a biotech company looking to disrupt a fast-growing...
Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (VKTX 1.00%), a biotech company looking to disrupt a fast-growing market. Analysts believe this drugmaker is severely undervalued: Viking Therapeutics' average price target of $92.72 (according to Yahoo! Finance) implies an upside of about 181% from its current levels. Should investors purchase shares of Viking Therapeutics right now? The next 18 months could be decisive Viking Therapeutics is developing therapies for chronic weight management. Given recent breakthroughs in this area -- and the fact that obesity is a serious, highly prevalent condition that is also linked to many others -- the weight-loss market is growing rapidly and will continue to do so well into the next decade. Naturally, this field is dominated by large and prominent pharmaceutical leaders, with many others looking to join the party. Viking Therapeutics is a fairly small player in the game, but it does have a somewhat realistic shot at carving a niche. The company's leading candidate, VK2735, is undergoing pivotal clinical trials, including one in adults with obesity and diabetes and another in obese patients without diabetes. Both will measure weight loss over 78 weeks. We should see results from these studies next year. Viking Therapeutics is also developing an oral version of VK2735, which it expects to advance to phase 3 studies in the third quarter. Expand NASDAQ : VKTX Viking Therapeutics Today's Change ( -1.00 %) $ -0.33 Current Price $ 32.65 Key Data Points Market Cap $3.8B Day's Range $ 32.54 - $ 33.59 52wk Range $ 18.92 - $ 43.15 Volume 11K Avg Vol 3M What's your risk tolerance? What would allow Viking Therapeutics to match Wall Street's average price ta...
Key Points Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is. The Street's optimism must be weighed against the risk Viking Therapeutics carries. 10 stocks we like better than Viking Therapeutics › Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the pas...
Key Points Viking Therapeutics' leading candidate should complete some ongoing phase 3 studies next year. The stock might soar, depending on how strong the data is. The Street's optimism must be weighed against the risk Viking Therapeutics carries. 10 stocks we like better than Viking Therapeutics › Some artificial intelligence (AI)-focused companies have delivered exceptional returns over the past few years, but some investors and analysts now believe we are in an AI bubble ready to burst. Even if that's not the case, it's worth considering stocks in other industries that could offer excellent returns. Take Viking Therapeutics (NASDAQ: VKTX), a biotech company looking to disrupt a fast-growing market. Analysts believe this drugmaker is severely undervalued: Viking Therapeutics' average price target of $92.72 (according to Yahoo! Finance) implies an upside of about 181% from its current levels. Should investors purchase shares of Viking Therapeutics right now? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The next 18 months could be decisive Viking Therapeutics is developing therapies for chronic weight management. Given recent breakthroughs in this area -- and the fact that obesity is a serious, highly prevalent condition that is also linked to many others -- the weight-loss market is growing rapidly and will continue to do so well into the next decade. Naturally, this field is dominated by large and prominent pharmaceutical leaders, with many others looking to join the party. Viking Therapeutics is a fairly small player in the game, but it does have a somewhat realistic shot at carving a niche. The company's leading candidate, VK2735, is undergoing pivotal clinical trials, including one in adults with obesity and diabetes and another in obese patients without diabetes. Both will measure weight...
Trump Cabinet Members Allegedly Buying Nuclear Bunkers Via Modernity.news, The Iran conflict has ignited a massive surge in demand for nuclear-proof bunkers across America , with even top Trump administration officials securing their own underground fortresses amid whispers of World War Three. As The Telegraph reports, Ron Hubbard, owner of Atlas Survival Shelters, reports being “inundated with ca...
Trump Cabinet Members Allegedly Buying Nuclear Bunkers Via Modernity.news, The Iran conflict has ignited a massive surge in demand for nuclear-proof bunkers across America , with even top Trump administration officials securing their own underground fortresses amid whispers of World War Three. As The Telegraph reports, Ron Hubbard, owner of Atlas Survival Shelters, reports being “inundated with calls” since the conflict erupted, with enquiries spiking “tenfold.” The Texas-based company, which builds everything from $20,000 basic shelters to multimillion-dollar compounds, is reaping a harvest from the heightened tensions. Hubbard revealed that two senior Trump Cabinet members are new customers. “One of them texted me yesterday, asking me: ‘When will my bunker be ready?’” he said. These bunkers boast hardened steel construction, armoured blast doors, air purification systems, and luxuries like cinemas, pools, and gun ranges—designed to withstand drone strikes or worse. Yet Hubbard is blunt about limits: “No bunker in the world is designed to withstand a bunker buster from an American bomber. I’m sorry you just can’t make a bunker strong enough.” He added: “If the Americans want you dead, you’re dead. I don’t think any bunker in the world can protect you from an American that wants to kill you.” The boom extends globally, with Hubbard’s new Dubai office fielding urgent requests after Iranian missiles hit the city. “They thought they’d never see bombs fall. But now [they’re getting the s— bombed out of them],” he noted of local clients. Atlas averaged $2 million in monthly sales this year but expects $50 million next month. “Bunker building is like being a farmer. When it’s time for harvest, you have to reap all you can,” Hubbard explained. “Now that they’ve been bombed, they’re all going to want shelters. It’s just a fact of life.” Hubbard has built for tech moguls like Mark Zuckerberg and even Andrew Tate, underscoring how elites are hedging against chaos. Tyler Durde...
Micron Technology (NASDAQ:MU - Get Free Report) had its price target raised by equities research analysts at Susquehanna from $345.00 to $525.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "positive" rating on the semiconductor manufacturer's stock. Susquehanna's price target would suggest a potential upside of 45.43% from the stock's p...
Micron Technology (NASDAQ:MU - Get Free Report) had its price target raised by equities research analysts at Susquehanna from $345.00 to $525.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "positive" rating on the semiconductor manufacturer's stock. Susquehanna's price target would suggest a potential upside of 45.43% from the stock's previous close. Several other equities analysts have also issued reports on the company. Morgan Stanley raised their price objective on Micron Technology from $350.00 to $450.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Piper Sandler raised their price target on Micron Technology from $275.00 to $400.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 7th. Mizuho lifted their price target on Micron Technology from $390.00 to $480.00 and gave the stock an "outperform" rating in a research report on Tuesday, January 27th. Rosenblatt Securities reiterated a "buy" rating and issued a $500.00 price objective on shares of Micron Technology in a research note on Tuesday, January 20th. Finally, Wedbush set a $320.00 price objective on Micron Technology in a report on Thursday, December 18th. Six investment analysts have rated the stock with a Strong Buy rating, twenty-nine have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $379.59. Get Micron Technology alerts: Sign Up Read Our Latest Analysis on MU Micron Technology Stock Down 2.5% Shares of MU traded down $9.30 during midday trading on Monday, hitting $361.00. The company had a trading volume of 7,218,095 shares, compared to its average volume of 35,418,762. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.78 and a current ratio of 2.46. The company's 50-day simple moving average is $379.98 and...
Michael M. Santiago/Getty Images News As broader markets grapple with geopolitical uncertainty, oil prices above $100 per barrel, and renewed concerns over global logistics disruptions due to Strait of Hormuz tensions, investors are likely watching out for pockets of stability. Here, we are scanning the healthcare sector for reliable dividend payers. Below is a list of healthcare companies current...
Michael M. Santiago/Getty Images News As broader markets grapple with geopolitical uncertainty, oil prices above $100 per barrel, and renewed concerns over global logistics disruptions due to Strait of Hormuz tensions, investors are likely watching out for pockets of stability. Here, we are scanning the healthcare sector for reliable dividend payers. Below is a list of healthcare companies currently offering some of the highest dividend yields in the sector. Oramed Pharmaceuticals ( ORMP ) - Dividend yield - 7.61%. Embecta ( EMBC ) - Dividend yield - 6.62%. Pfizer ( PFE ) - Dividend yield - 6.36%. DENTSPLY SIRONA ( XRAY ) - Dividend yield - 5.02%. National Research ( NRC ) - Dividend yield - 4.39%. Bristol-Myers Squibb ( BMY ) - Dividend yield - 4.18%. CVS Health ( CVS ) - Dividend yield - 3.41%. Viatris ( VTRS ) - Dividend yield - 3.39%. UnitedHealth ( UNH ) - Dividend yield - 3.09%. Abbvie ( ABBV ) - Dividend yield - 3.01%. More on healthcare stocks The Scotts Miracle-Gro Company (SMG) Presents at 47th Annual Raymond James Institutional Investor Conference - Slideshow CVS Health: Stop Catastrophizing, Start Believing - Here's Why Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie sees promising early-stage data for weight loss asset ABBV-295 Bristol Myers cancer drug meets main goal in late-stage study
In early trading on Monday, shares of Procter & Gamble topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.7%. Year to date, Procter & Gamble registers a 7.9% gain. And the worst performing Dow component thus far on the day is Cisco Systems, trading down 2.9%. Cisco Systems is lower by about 0.9% looking at the year to date performance. Two other comp...
In early trading on Monday, shares of Procter & Gamble topped the list of the day's best performing Dow Jones Industrial Average components, trading up 0.7%. Year to date, Procter & Gamble registers a 7.9% gain. And the worst performing Dow component thus far on the day is Cisco Systems, trading down 2.9%. Cisco Systems is lower by about 0.9% looking at the year to date performance. Two other components making moves today are Home Depot, trading down 2.5%, and Johnson & Johnson, trading up 0.4% on the day. VIDEO: Dow Movers: CSCO, PG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.